
Oyster Point Pharma OYST
Quarterly report 2022-Q3
added 11-10-2022
Oyster Point Pharma ROA Ratio 2011-2026 | OYST
Annual ROA Ratio Oyster Point Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -45.22 | -35.63 | -31.92 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -31.92 | -45.22 | -37.59 |
Quarterly ROA Ratio Oyster Point Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -95.45 | -104.51 | -79.92 | -58.85 | -32.93 | -44.16 | -43.34 | -37.52 | -35.63 | -38.17 | -37.96 | -37.64 | -31.92 | -88.47 | -196.71 | -189.21 | -186.59 | -116.27 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -31.92 | -196.71 | -80.85 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | ||
|
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M | ||
|
Celldex Therapeutics
CLDX
|
-44.38 | $ 34.55 | 2.04 % | $ 2.29 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 4.47 | 12.59 % | $ 10.8 B | ||
|
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-36.12 | $ 5.8 | 13.28 % | $ 391 B | ||
|
Aligos Therapeutics
ALGS
|
-27.33 | $ 6.68 | -12.79 % | $ 66 M | ||
|
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 309.66 | -3.27 % | $ 40.6 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | ||
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 22.88 | 4.91 % | $ 1.07 B | ||
|
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
65.02 | $ 102.92 | 0.78 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - | ||
|
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.04 | -1.3 % | $ 5 M | ||
|
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
-155.62 | $ 1.15 | 7.48 % | $ 14 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.41 | 4.07 % | $ 363 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.32 | 1.41 % | $ 462 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.53 | 1.41 % | $ 3.12 B | ||
|
Burford Capital Limited
BUR
|
5.51 | $ 4.96 | 6.1 % | $ 792 M | ||
|
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | ||
|
Cabaletta Bio
CABA
|
-101.68 | $ 3.44 | -2.27 % | $ 346 M | ||
|
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.6 | -0.62 % | $ 426 M | ||
|
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | ||
|
Citius Pharmaceuticals
CTXR
|
-33.8 | $ 0.86 | 0.39 % | $ 5.79 M | ||
|
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | ||
|
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B |